HIV-related Pneumocystis carinii pneumonia in older patients hospitalized in the early HAART era

Kim, Benjamin; Lyons, Thomas M.; Parada, Jorge P.; Uphold, Constance R.; Yarnold, Paul R.; Hounshell, Jennie B.; Sipler, Alison M.; Goetz, Matthew B.; DeHovitz, Jack A.; Weinstein, Robert A.; Campo, Rafael E.; Bennett, Charles L.; Kim, B; Lyons, T M; Parada, J P; Uphold, C R; Yarnold, P R; Hounshell, J B; Sipler, A M; Goetz, M B
September 2001
JGIM: Journal of General Internal Medicine;Sep2001, Vol. 16 Issue 9, p583
Academic Journal
journal article
Objective: To determine whether older age continues to influence patterns of care and in-hospital mortality for hospitalized persons with HIV-related Pneumocystis carinii pneumonia (PCP), as determined in our prior study from the 1980s.Design: Retrospective chart review.Patients/setting: Patients (1,861) with HIV-related PCP at 78 hospitals in 8 cities from 1995 to 1997.Measurements: Medical record notation of possible HIV infection; alveolar-arterial oxygen gradient; CD4 lymphocyte count; presence or absence of wasting; timely use of anti-PCP medications; in-hospital mortality.Main Results: Compared to younger patients, patients > or =50 years of age were less likely to have HIV mentioned in their progress notes (70% vs 82%, P <.001), have mild or moderately severe PCP cases at admission (89% vs 96%, P <.002), receive anti-PCP medications within the first 2 days of hospitalization (86% vs 93%, P <.002), and survive hospitalization (82% vs 90%, P <.003). However, age was not a significant predictor of mortality after adjustment for severity of PCP and timeliness of therapy.Conclusions: While inpatient PCP mortality has improved by 50% in the past decade, 2-fold age-related mortality differences persist. As in the 1980s, these differences are associated with lower rates of recognition of HIV, increased severity of illness at admission, and delays in initiation of PCP-specific treatments among older individuals--factors suggestive of delayed recognition of HIV infection, pneumonia, and PCP, respectively. Continued vigilance for the possibility of HIV and HIV-related PCP among persons > or =50 years of age who present with new pulmonary symptoms should be encouraged.


Related Articles

  • Enzyme-linked immunosorbent assay and serologic responses to Pneumocystis jiroveci. Daly, Kieran R.; Koch, Judy; Levin, Linda; Walzer, Peter D. // Emerging Infectious Diseases;May2004, Vol. 10 Issue 5, p848 

    Seroepidemiologic studies of Pneumocystis pneumonia (PCP) in humans have been limited by inadequate reagents. We have developed an enzyme-linked immunosorbent assay (ELISA) using three overlapping recombinant fragments of the human Pneumocystis major surface glycoprotein (MsgA, MsgB, and MsgC)...

  • HIV+ Patients Still Need PCP Prophylaxis. Kemper, Carol A. // Infectious Disease Alert;Apr2007, Vol. 26 Issue 7, p83 

    This article discusses findings of a study which focused on human-immunodeficiency virus-infected patients who still need Pneumocystis pneumonia (PCP) prophylaxis. From 1999-2003, a total of 483 cases were diagnosed. A low incidence of PCP was observed in persons receiving both highly active...

  • Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy. Chien-Yu Cheng; Mao-Yuan Chen; Szu-Min Hsieh; Wang-Huei Sheng; Hsin-Yun Sun; Yi-Chun Lo; Wen-Chun Liu; Chien-Ching Hung // BMC Infectious Diseases;2010, Vol. 10 Issue 1, p126 

    Background: Risk of pneumocystosis after discontinuation of primary or secondary prophylaxis among HIV-infected patients before CD4 counts increase to Λ200 cells/μL (early discontinuation) after receiving highly active antiretroviral therapy (HAART) is rarely investigated. Methods:...

  • Jail inmates and HIV care: provision of antiretroviral therapy and Pneumocystis carinii pneumonia prophylaxis. White, M. C.; Mehrotra, A.; Menendez, E.; Estes, M.; Goldenson, J.; Tulsky, J. P. // International Journal of STD & AIDS;Jun2001, Vol. 12 Issue 6, p380 

    The objective of this study was to examine prescription and acceptance of antiretroviral therapy (ART) and Pneumocystis carinii pneumonia (PCP) prophylaxis in jail and at release. A retrospective cross sectional design was used, by record review, of 77 inmates receiving HIV-related care in the...

  • Analysis of Underlying Diseases and Prognosis Factors Associated with Pneumocystis carinii Pneumonia in Immunocompromised HIV-Negative Patients. Roblot, F.; Godet, C.; Moal, G. Le; Garo, B.; Faouzi Souala, M.; Dary, M.; de Gentile, L.; Gandji, J.; Guimard, Y.; Lacroix, C.; Roblot, P.; Becq-Giraudon, B. // European Journal of Clinical Microbiology & Infectious Diseases;Jul2002, Vol. 21 Issue 7, p523 

    The aim of this retrospective study was to determine the underlying diseases associated with Pneumocystis carinii pneumonia (PCP) in immunocompromised HIV-negative patients and to identify prognosis factors in this population. One hundred three cases of PCP were diagnosed over a 5-year period....

  • Discontinuation of Primary Prophylaxis for Pneumocystis carinii Pneumonia and Toxoplasmic... Mussini, Cristina; Pezzotti, Patrizio; Govoni, Alessandra; Borghi, Vanni; Antinori, Andrea; d'Arminio Monforte, Antonella; De Luca, Andrea; Mongiardo, Nicola; Cerri, Maria Chiara; Chiodo, Francesco; Concia, Ercole; Bonazzi, Lucio; Moroni, Mauro; Ortona, Luigi; Esposito, Robert; Cossarizza, Andrea; De Rienzo, Bruno // Journal of Infectious Diseases;5/1/2000, Vol. 181 Issue 5, p1635 

    Examines the discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in patients infected with HIV-type 1 whose CD4[sup +] T cell counts have increased to 200 cells per cubic millimeter as a result of highly active antiretrovial therapy (HAART). ...

  • Pneumocystis carinii pneumonia.  // Modern Medicine;Aug95, Vol. 63 Issue 8, p26 

    Reports on the US Food and Drug Administration's approval on the marketing of a suspension form of atovaquone in the treatment of pneumocystis carinii pneumonia. Advantages and convenience; Dosage.

  • Pneumocystis carinii pneumonia prophylaxis reduces mortality, costs.  // Formulary;Sep95, Vol. 30 Issue 9, p544 

    Presents an abstract of the article `The impact of prophylaxis on outcome and resource utilization in Pneumocystis carinii pneumonia,' by J.E. Gallant, S.M. McAvinue, R.D. Moore et al, which appeared in the 1995 issue of `Chest' periodical.

  • Current management practices in the treatment of Pneumocystis carinii pneumonia (PCP). Blanchet, Kevin D. // AIDS Patient Care & STDs;Apr96, Vol. 10 Issue 2, p116 

    Presents a dialogue on current management practices in the treatment of Pneumocystis carinii pneumonia (PCP). Prophylaxis and compliance; Treatment of mild PCP; Patient management issues.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics